The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

Publisher： Karger

E-ISSN： 1421-9794|58|1|60-69

ISSN： 0009-3157

Source： Chemotherapy, Vol.58, Iss.1, 2012-02, pp. : 60-69

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of Docetaxel as a Second-Line Chemotherapy for Thymic Carcinoma

By  

Chemotherapy, Vol. 50, Iss. 6, 2004-12 ,pp. : 279-282

Karger

Access to resources Recommend Favorite

A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma

By  

Chemotherapy, Vol. 55, Iss. 5, 2009-07 ,pp. : 321-326

Karger

Access to resources Recommend Favorite

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy

By  

Chemotherapy, Vol. 59, Iss. 4, 2014-01 ,pp. : 273-279

Karger

Access to resources Recommend Favorite

Second-Line Combination Chemotherapy with Docetaxel for Cisplatin-Pretreated Refractory Metastatic Esophageal Cancer: A Preliminary Report of Initial Experience

By  

Chemotherapy, Vol. 53, Iss. 6, 2007-10 ,pp. : 449-453

Karger

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 472-477

Karger

Access to resources Recommend Favorite